The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.
ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.
Accompanying slides from the TREK-AD topline data readout
VIEW MOREEblasakimab Monthly Dosing Shows Potential for Best-in-class Therapy in Positive Phase 2b Study in Atopic Dermatitis
VIEW MOREASLAN Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
VIEW MOREASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in two Late-breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
VIEW MOREASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at The 1st International Societies For Investigative Dermatology Meeting
VIEW MOREASLAN Pharmaceuticals Announces Acceptance of Two Abstracts For Poster Presentation at The 1st International Societies For Investigative Dermatology Meeting
VIEW MOREASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
VIEW MOREASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients
VIEW MOREASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for E-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting
VIEW MORE